The fbpA/sapM double knock out strain of Mycobacterium tuberculosis is highly attenuated and immunogenic in macrophages

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Saikolappan, Sankaralingam ^a   Estrella, Jaymie ^b   Sasindran, Smitha J ^a   Khan, Arshad ^b   Armitige, Lisa Y ^b   Jagannath, Chinnaswamy ^b   Dhandayuthapani, Subramanian ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; BAFILOMYCIN; BCG VACCINE; RAB7 PROTEIN; TUBERCULOSTATIC AGENT; ACYLTRANSFERASE; ANTIGEN 85A, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; LIVE VACCINE;

ANTIGEN PRESENTING CELL; ARTICLE; BACTERIAL STRAIN; CAUSE OF DEATH; CONTROLLED STUDY; IMMUNOGENICITY; IN VITRO STUDY; LYSOSOME; MACROPHAGE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHAGOSOME; T LYMPHOCYTE; TH1 CELL; TUBERCULOSIS; WILD TYPE; ANIMAL; GENE INACTIVATION; GENETICS; IMMUNOLOGY; MOUSE; MUTATION;

BACTERIA (MICROORGANISMS); MUS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; GENE KNOCKOUT TECHNIQUES; LYSOSOMES; MACROPHAGES; MICE; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHAGOSOMES; VACCINES, ATTENUATED;

EID: 84860502287     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036198     Document Type: Article

References (67)

1. Andersen P, Doherty TM, (2005) The success and failure of BCG- implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662.
2. Fine PE, (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345.
3. Izzo A, Brandt L, Lasco T, Kipnis AP, Orme I, (2005) NIH pre-clinical screening program: overview and current status. Tuberculosis (Edinb) 85: 25-28.
4. Andersen P, (2001) TB vaccines: progress and problems. Trends Immunol 22: 160-168.
5. Skeiky YA, Sadoff JC, (2006) Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4: 469-476.
6. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P, (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69: 2773-2778.
7. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, et al. (2005) Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 174: 6332-6339.
8. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S, (2000) Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97: 13853-13858.
9. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, et al. (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9: 533-539.
10. Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, et al. (1998) Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci U S A 95: 5299-5304.
11. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115: 2472-2479.
12. Andersen P, (2007) Tuberculosis vaccines- an update. Nat Rev Microbiol 5: 484-487.
13. Armitige LY, Jagannath C, Wanger AR, Norris SJ, (2000) Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect Immun 68: 767-778.
14. Copenhaver RH, Sepulveda E, Armitige LY, Actor JK, Wanger A, et al. (2004) A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential. Infect Immun 72: 7084-7095.
15. Jackson M, Phalen SW, Lagranderie M, Ensergueix D, Chavarot P, et al. (1999) Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect Immun 67: 2867-2873.
16. Hondalus MK, Bardarov S, Russell R, Chan J, Jacobs WR Jr, et al. (2000) Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun 68: 2888-2898.
17. Smith DA, Parish T, Stoker NG, Bancroft GJ, (2001) Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 69: 1142-1150.
18. Pavelka MS Jr, Chen B, Kelley CL, Collins FM, Jacobs WR Jr, (2003) Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect Immun 71: 4190-4192.
19. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, et al. (2002) A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8: 1171-1174.
20. Larsen MH, Biermann K, Chen B, Hsu T, Sambandamurthy VK, et al. (2009) Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 27: 4709-4717.
21. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, et al. (2006) Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24: 6309-6320.
22. Roy E, De Silva AD, Sambandamurthy VK, Clark SO, Stavropoulos E, et al. (2006) Induction of high levels of protective immunity in mice after vaccination using dendritic cells infected with auxotrophic mutants of Mycobacterium tuberculosis. Immunol Lett 103: 196-199.
23. Sambandamurthy VK, Jacobs WR Jr, (2005) Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 7: 955-961.
24. Sambandamurthy VK, Derrick SC, Jalapathy KV, Chen B, Russell RG, et al. (2005) Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun 73: 1196-1203.
25. Infante E, Aguilar LD, Gicquel B, Pando RH, (2005) Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant. Clin Exp Immunol 141: 21-28.
26. Aguilar LD, Infante E, Bianco MV, Cataldi A, Bigi F, et al. (2006) Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis. Vaccine 24: 2333-2342.
27. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, et al. (2006) The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24: 3408-3419.
28. Aguilar D, Infante E, Martin C, Gormley E, Gicquel B, et al. (2007) Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain. Clin Exp Immunol 147: 330-338.
29. Asensio JA, Arbues A, Perez E, Gicquel B, Martin C, (2008) Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Expert Opin Biol Ther 8: 201-211.
30. Henao-Tamayo M, Junqueira-Kipnis AP, Ordway D, Gonzales-Juarrero M, Stewart GR, et al. (2007) A mutant of Mycobacterium tuberculosis lacking the 19-kDa lipoprotein Rv3763 is highly attenuated in vivo but retains potent vaccinogenic properties. Vaccine 25: 7153-7159.
31. Hernandez Pando R, Aguilar LD, Smith I, Manganelli R, (2010) Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary tuberculosis. Infect Immun 78: 3168-3176.
32. Hinchey J, Jeon BY, Alley H, Chen B, Goldberg M, et al. (2011) Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis. PLoS One 6: e15857.
33. Cooper AM, (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393-422.
34. Parida SK, Kaufmann SH, (2010) Novel tuberculosis vaccines on the horizon. Curr Opin Immunol 22: 374-384.
35. Orme IM, (2005) The use of animal models to guide rational vaccine design. Microbes Infect 7: 905-910.
36. Armstrong JA, Hart PD, (1975) Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J Exp Med 142: 1-16.
37. Russell DG, (1998) What does 'inhibition of phagosome-lysosome fusion' really mean? Trends Microbiol 6: 212-214.
38. Russell DG, (2001) Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2: 569-577.
39. Russell DG, (2003) Phagosomes, fatty acids and tuberculosis. Nat Cell Biol 5: 776-778.
40. Via LE, Deretic D, Ulmer RJ, Hibler NS, Huber LA, et al. (1997) Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7. J Biol Chem 272: 13326-13331.
41. Clemens DL, (1996) Characterization of the Mycobacterium tuberculosis phagosome. Trends Microbiol 4: 113-118.
42. Pancholi P, Mirza A, Bhardwaj N, Steinman RM, (1993) Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages. Science 260: 984-986.
43. Singh CR, Moulton RA, Armitige LY, Bidani A, Snuggs M, et al. (2006) Processing and presentation of a mycobacterial antigen 85B epitope by murine macrophages is dependent on the phagosomal acquisition of vacuolar proton ATPase and in situ activation of cathepsin D. J Immunol 177: 3250-3259.
44. Soualhine H, Deghmane AE, Sun J, Mak K, Talal A, et al. (2007) Mycobacterium bovis bacillus Calmette-Guerin secreting active cathepsin S stimulates expression of mature MHC class II molecules and antigen presentation in human macrophages. J Immunol 179: 5137-5145.
45. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, et al. (2009) Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med 15: 267-276.
46. Katti MK, Dai G, Armitige LY, Rivera Marrero C, Daniel S, et al. (2008) The Delta fbpA mutant derived from Mycobacterium tuberculosis H37Rv has an enhanced susceptibility to intracellular antimicrobial oxidative mechanisms, undergoes limited phagosome maturation and activates macrophages and dendritic cells. Cell Microbiol 10: 1286-1303.
47. Saleh MT, Belisle JT, (2000) Secretion of an acid phosphatase (SapM) by Mycobacterium tuberculosis that is similar to eukaryotic acid phosphatases. J Bacteriol 182: 6850-6853.
48. Vergne I, Chua J, Lee HH, Lucas M, Belisle J, et al. (2005) Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 102: 4033-4038.
49. Venketaraman V, Talaue MT, Dayaram YK, Peteroy-Kelly MA, Bu W, et al. (2003) Nitric oxide regulation of L-arginine uptake in murine and human macrophages. Tuberculosis (Edinb) 83: 311-318.
50. Vergne I, Fratti RA, Hill PJ, Chua J, Belisle J, et al. (2004) Mycobacterium tuberculosis phagosome maturation arrest: mycobacterial phosphatidylinositol analog phosphatidylinositol mannoside stimulates early endosomal fusion. Mol Biol Cell 15: 751-760.
51. Ferrer NL, Gomez AB, Neyrolles O, Gicquel B, Martin C, (2010) Interactions of attenuated Mycobacterium tuberculosis phoP mutant with human macrophages. PLoS One 5: e12978.
52. Ramachandra L, Smialek JL, Shank SS, Convery M, Boom WH, et al. (2005) Phagosomal processing of Mycobacterium tuberculosis antigen 85B is modulated independently of mycobacterial viability and phagosome maturation. Infect Immun 73: 1097-1105.
53. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK, (1996) Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 178: 1274-1282.
54. Brosch R, Gordon SV, Eiglmeier K, Garnier T, Tekaia F, et al. (2000) Genomics, biology and evolution of Mycobacterium tuberculosis complex. In: Hatfull G, Jacobs WRJ, editors. Molecular genetics of Mycobacteria Washington, DC American Society for Microbiology pp. 19-36.
55. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, et al. (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284: 1520-1523.
56. Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K, et al. (1999) Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol 32: 643-655.
57. Ramachandra L, Noss E, Boom WH, Harding CV, (2001) Processing of Mycobacterium tuberculosis antigen 85B involves intraphagosomal formation of peptide-major histocompatibility complex II complexes and is inhibited by live bacilli that decrease phagosome maturation. J Exp Med 194: 1421-1432.
58. Roche CM, Singh CR, Lindsey DR, Smith AK, Armitige LY, et al. (2011) The delta fbpA vaccine induces a stronger T-bet dependent immunity in mice against tuberculosis. Journal of Vaccine and Vaccination (submitted).
59. Kwan CK, Ernst JD, (2011) HIV and Tuberculosis: a Deadly Human Syndemic. Clin Microbiol Rev 24: 351-376.
60. Festjens N, Bogaert P, Batni A, Houthuys E, Plets E, et al. (2011) Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis. EMBO Mol Med 3: 222-234.
61. Parish T, Stoker NG, (2000) Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology 146 (Pt 8): 1969-1975.
62. Jacobs WR Jr, Kalpana GV, Cirillo JD, Pascopella L, Snapper SB, et al. (1991) Genetic systems for mycobacteria. Methods Enzymol 204: 537-555.
63. Ausubel F, Brent R, Kingston R, Moore D, Seidman J, et al. (1989) Current Prtocols in Molecular Biology. New York Wiley.
64. van Soolingen D, Hermans PW, (1995) Epidemiology of tuberculosis by DNA fingerprinting. Eur Respir J (Suppl 20): 649s-656s.
65. Dhandayuthapani S, (2007) Stress response of genes encoding putative stress signaling molecules of Mycobacterium tuberculosis. Front Biosci 12: 4676-4681.
66. Douglas T, Daniel DS, Parida BK, Jagannath C, Dhandayuthapani S, (2004) Methionine sulfoxide reductase A (MsrA) deficiency affects the survival of Mycobacterium smegmatis within macrophages. J Bacteriol 186: 3590-3598.
67. Daniel DS, Dai G, Singh CR, Lindsey DR, Smith AK, et al. (2006) The reduced bactericidal function of complement C5-deficient murine macrophages is associated with defects in the synthesis and delivery of reactive oxygen radicals to mycobacterial phagosomes. J Immunol 177: 4688-4698.